Extended indication Lisocabtagene maraleucel monotherapy for third line or later treatment of relapsed or refractory fol
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information